February 7, 2022 02:13 PM ESTUpdated 05:24 PM
Pharma

As­traZeneca ter­mi­nates US pen­sion plan — will oth­er phar­mas fol­low?

Paul Schloesser

Associate Editor

As­traZeneca’s US sub­sidiary is ax­ing its $1.3 bil­lion-dol­lar pen­sion plan this year, mark­ing an end of an era as an­oth­er group of re­tire­ment funds at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times